Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10703683 | 0.69 | CYP1A2 (0.48) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL1583643 | 0.69 | CYP1A2 (0.36) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL270802 | 0.69 | CA12 (0.36) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL269710 | 0.69 | CYP1A2 (0.36) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL65000 | 0.68 | CYP1A2 (0.53) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL1583184 | 0.67 | CYP1A2 (0.35) | CYP1A2MAPK1 | |
| Ammonia Solution, Strong SCHEMBL5964780 | 0.65 | CYP1A2 (0.50) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL8021435 | 0.65 | CYP1A2 (0.50) | CYP1A2MAPK1CA12CA1CA2 | |
| Fluoride SCHEMBL1056432 | 0.65 | CYP1A2 (0.50) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL27552946 | 0.65 | CYP1A2 (0.50) | CYP1A2MAPK1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRM1 | CYP1A2 420/4885MAPK1 3617/4885CA12 4620/4885 |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CYP1A2 268/4885MAPK1 3809/4885CA12 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.